The Antibody and Recombinant Protein CDMO Market Size is valued at USD 16.2 billion in 2023 and is predicted to reach USD 36.1 billion by the year 2031 at a 10.8% CAGR during the forecast period for 2024-2031.
The antibody and recombinant protein CDMO (Contract Development and Manufacturing Organization) market is a subset of the biopharmaceutical industry that is focused on the development as well as production of recombinant proteins and antibodies. CDMOs provide comprehensive end-to-end services for biotechnology and pharmaceutical firms, encompassing everything from early-stage research, including cell line development and process optimization, to large-scale manufacturing, regulatory support, and final product commercialization. The market for antibody and recombinant protein CDMO is anticipated to develop significantly over the next several years due to a number of causes, including the rising incidence of chronic illnesses, the growing need for tailored therapy, and biotechnology advancements. The increasing practice of pharmaceutical companies outsourcing manufacturing services to CDMOs is driving the market as well.
Furthermore, several companies in the fiercely competitive antibody and recombinant protein CDMO industry provide a variety of services, such as cell line creation, antibody production, and recombinant protein expression. In order to get a competitive edge, market participants are also concentrating on growing the range of services they offer, making investments in research and development, and forming strategic alliances.
The antibody and recombinant protein CDMO market is segmented based on type and application. Based on type, the market is segmented into Antibody CDMO and Recombinant Protein CDMO. As per application segment, the market is segmented into Pharmaceutical Company, Biotechnology Company, and Generic Company.
The antibody CDMO category is expected to hold a major global market share in 2023, driven by the growing need for biological medicines, in particular monoclonal antibodies, which are being utilized more and more to treat infectious diseases, autoimmune disorders, and cancer, among other chronic illnesses. A unique set of skills that CDMOs may offer is efficient and scalable production, which is required in light of the increasing investments in biotechnology and the need for novel therapeutic solutions. Furthermore, the productivity and economy of antibody production are being improved by developments in bioprocessing technologies, such as continuous manufacturing and single-use systems.
The growth of biotechnology companies is propelled by the rising need for biologics, specifically recombinant proteins and monoclonal antibodies, which are crucial for creating novel treatments. Leading this surge are biotechnology companies, using cutting-edge technologies and specialized knowledge to address the intricate needs of producing biologics. Biotechnology businesses are key actors in the CDMO landscape as a result of the increased emphasis on customized treatment and the rise in chronic diseases, which drive up demand for these biologics.
The North American antibody and recombinant protein CDMO market is expected to note the highest market share in revenue in the near future. The main nations in North America that are propelling market expansion are the United States and Canada. Significant elements fostering market expansion in this area include the existence of significant biotechnology and pharmaceutical firms as well as an established healthcare system. There is a growing need for personalized medicine, and the area is experiencing a rise in investments in healthcare infrastructure. Additionally, the region's increasing emphasis on research and development initiatives is fueling the market's expansion. In addition, Asia Pacific is likely to grow rapidly in the global market. Some of the important drivers of market expansion in the Asia Pacific region include rising investments in the biotechnology and healthcare sectors as well as rising biologics demand.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 16.2 Bn |
|
Revenue Forecast In 2031 |
USD 36.1 Bn |
|
Growth Rate CAGR |
CAGR of 10.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, And Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Batavia Biosciences, Grifols,Biovian Oy, Catalent, Bioinnobio, Thousand Oaks Biopharmaceuticals, Goodwin Biotechnology, Cerbios-Pharma SA, HALIX, Merck, Hangzhou Hs-biopharm, Wuxibiologics, Cerbios-Pharma SA, Genscriptprobio, Vetter, Etinpro (Beijing) Co, Boehringer Ingelheim BioXcellence, Eurogentec, HJB, Bibo Pharma, MabPlex International, Lonza, 3SBio Inc, and Porton. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibody and Recombinant Protein CDMO Market Snapshot
Chapter 4. Global Antibody and Recombinant Protein CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Antibody CDMO
5.2.2. Recombinant Protein CDMO
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Pharmaceutical Company
6.2.2. Biotechnology Company
6.2.3. Generic Company
Chapter 7. Antibody and Recombinant Protein CDMO Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.1.2. North America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.1.3. North America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.2. Europe
7.2.1. Europe Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.2.2. Europe Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.2.3. Europe Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.3.2. Asia Pacific Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.3.3. Asia Pacific Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.4. Latin America
7.4.1. Latin America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.4.2. Latin America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.4.3. Latin America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.5.2. Middle East & Africa Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.5.3. Middle East & Africa Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Batavia Biosciences
8.2.2. Cerbios-Pharma SA
8.2.3. Grifols
8.2.4. HALIX
8.2.5. Biovian Oy
8.2.6. Catalent
8.2.7. Goodwin Biotechnology
8.2.8. Merck
8.2.9. Hangzhou Hs-biopharma
8.2.10. Wuxibiologics
8.2.11. Bioinnobio
8.2.12. Thousand Oaks Biopharmaceuticals
8.2.13. Cerbios-Pharma SA
8.2.14. Eurogentec
8.2.15. HJB
8.2.16. Bibo Pharma
8.2.17. MabPlex International
8.2.18. Genscriptprobio
8.2.19. Vetter
8.2.20. Etinpro (Beijing) Co
8.2.21. Boehringer Ingelheim BioXcellence
8.2.22. Lonza
8.2.23. 3SBio Inc
8.2.24. Porton
8.2.25. Other Prominent Players
Antibody and Recombinant Protein CDMO Market By Type-
Antibody and Recombinant Protein CDMO Market By Application-
Antibody and Recombinant Protein CDMO Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
